Virtual Reality a Novel Screening and Treatment Aid in Attention Deficit Disorder

This study has been completed.

Sponsor:

ClinicalTrials.gov Identifier:

NCT00364702

First Posted: August 16, 2006

Last Update Posted: August 17, 2011

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

Information provided by:

Shaare Zedek Medical Center

Purpose

Using a virtual reality program in screening and treatment of ADHD.

Condition	Intervention	Phase
ADHD	Drug: methylphenidate	Phase 2


Study Type:	Interventional
Study Design:	Allocation: Non-Randomized Intervention Model: Factorial Assignment Masking: None (Open Label) Primary Purpose: Diagnostic
Official Title:	Virtual Reality a Novel Screening and Treatment Aid in Attention Deficit Disorder

Resource links provided by NLM:

MedlinePlus related topics: Attention Deficit Hyperactivity Disorder

Drug Information available for: Methylphenidate Methylphenidate hydrochloride

U.S. FDA Resources

Further study details as provided by Shaare Zedek Medical Center:

Primary Outcome Measures:

Virtual Reality program test results


Estimated Enrollment:	40
Study Start Date:	August 2006
Study Completion Date:	July 2007
Primary Completion Date:	July 2007 (Final data collection date for primary outcome measure)

Detailed Description:

Virtual Reality is a novel program designed to imitate a real classroom environment including various distractions. It includes a head monitor to track eye movements Children aged 10-20 years with ADHD will use the program with and without methylphenidate(1 mg/kg). Their results will be compared to a control group.

Parental consent will be obtained.

Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:	10 Years to 20 Years (Child, Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Clinical diagnosis of ADHD-DSM4 criteria AGE 10-20 YEARS normal neurological examination IQ>80

Exclusion Criteria:

ABNORMAL NEUROLOGICAL STATUS

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00364702

Locations


Israel
Shaari Zedek Pediatric Neurology Unit
Jerusalem, Israel, 91031

Sponsors and Collaborators

Shaare Zedek Medical Center

Investigators


Study Chair:	V. Gross, Prof/ md	Shaari Zedek Pediatric Neurology Unit

More Information


ClinicalTrials.gov Identifier:	NCT00364702 History of Changes
Other Study ID Numbers:	45/04
First Submitted:	August 15, 2006
First Posted:	August 16, 2006
Last Update Posted:	August 17, 2011
Last Verified:	July 2006

Keywords provided by Shaare Zedek Medical Center:


Virtual Reality ADHD Methylphenidate

Additional relevant MeSH terms:


Attention Deficit Disorder with Hyperactivity Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental Disorders Methylphenidate Central Nervous System Stimulants Physiological Effects of Drugs	Dopamine Uptake Inhibitors Neurotransmitter Uptake Inhibitors Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action Dopamine Agents Neurotransmitter Agents

To Top